NCT00439335 - Higher Dose Intradermal H5 Vaccine | Biotech Hunter

Enrollment

227

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Influenza

Interventions

BIOLOGICAL

Inactivated Influenza A Vaccine A/H5N1

Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.

BIOLOGICAL

Inactivated Influenza A Vaccine A/H5N1

Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.

DRUG

Placebo (IM)

The placebo will be 0.1 mL of saline administered by the IM route.

DRUG

Placebo (ID)

The placebo will be 0.1 mL of saline administered by the ID route.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH